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Abstract
Objectives: Neoadjuvant chemoradiotherapy (CRT) is a viable treatment strategy for patients with
pancreatic cancer. This study was conducted to evaluate the Virginia Mason Protocol (5-fluorouracil,
cisplatin, interferon-a and radiation) given in the neoadjuvant setting for the treatment of locally advanced
pancreatic cancer.
Methods: A Phase II pilot study evaluating interferon-based neoadjuvant CRT in patients with locally
advanced pancreatic cancer was performed.
Results: A total of 23 patients were enrolled. The mean age of the patients was 58.6 years. Of the 23
patients, seven (30.4%) completed all treatments. In the remaining 16 (69.6%) patients, treatment was
interrupted as a result of toxicity. The most commonly reported effects of toxicity were leucopoenia/
cytopoenia (n = 19, 82.6%) and gastrointestinal effects (n = 19, 82.6%). Surgical resection was successful
in seven (30.4%) patients. Margins were negative in six (85.7%) of these seven patients. Positive lymph
nodes were identified in three (42.9%) of seven patients. Overall survival was 11.5 months. Surgery
provided improved survival (22.6 months) compared with CRT alone (8.8 months). Disease-free survival
in resected patients was 17.2 months.
Conclusions: Interferon-based neoadjuvant CRT may allow for resection of locally advanced pancreatic
cancer, but with significant toxicity. In the absence of surgical resection, survival remains dismal.
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Introduction
Pancreatic cancer is a highly lethal disease; an estimated 43 140
new cases are diagnosed and 36 800 deaths occur in the USA each
year. Of newly diagnosed patients, approximately 80% will have
inoperable disease at presentation as a result of locally advanced
stage or metastases.1 As surgery offers the only possibility of cure,
efforts have been made to increase the percentage of patients
with locally advanced disease who are ultimately able to undergo
resection with curative intent. Multiple investigators have
reported rates of successful resection following neoadjuvant
5-fluorouracil (5-FU)-based chemoradiotherapy (CRT) that
range from <3% to 30%.2–7 Snady and colleagues used cisplatin in
combination neoadjuvant CRT in patients with locally advanced
disease and found the combination to be associated with resecta-
bility rates of >80%.7 Subsequent to this promising report, several
additional small trials have reported responses to neoadjuvant
cisplatin-based CRT in the order of 45% to nearly 60%.8,9
Interferon-a (IFN-a), a cytokine with direct and indirect anti-
tumor effects, has shown promising improvements in survival in
multimodal adjuvant therapy. This was first reported by the Vir-
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ginia Mason Medical Center (VMMC) group, who found a statis-
tically significant improvement in survival over 5-FU-based
adjuvant therapy at 26 months of follow-up, with 84% actuarial
survival at 2 years.10 A subsequent Phase II study by Linehan and
colleagues using combination CRT with post-radiation gemcitab-
ine instead of 5-FU resulted in a 2-year actuarial survival rate of
56%,11 which is identical to that reported by Picozzi and col-
leagues in the multicentre Phase II ACOSOG Z05031 trial.12 The
regimen initially described by the VMMC group includes IFN,
cisplatin, 5-FU and radiation given concurrently (for 5.5–6.0
weeks), followed by continuous infusion of 5-FU (two courses of
6 weeks each).10
Given the remarkable outcomes reported by the VMMC, the
present authors proposed to use this regimen in the preoperative
setting in patients with locally advanced unresectable pancreas
cancers in an effort to improve resectability rates. The present
report describes a single-arm, Phase II trial of IFN-based chemo-
radiation given in the neoadjuvant setting. The study hypothesis
was that neoadjuvant IFN-based CRT delivered as in the
ACOSOG Z05031 trial would result in improved rates of resecta-
bility and provide superior overall survival (OS).
Materials and methods
The primary objective of this single-arm, Phase II pilot study was
to determine the effect of neoadjuvant therapy with IFN, cisplatin,
5-FU and radiation in converting patients with locally advanced
adenocarcinoma of the pancreas to resectable status. The second-
ary objectives were to determine the rate and severity of early and
late toxicities, to improve the surgical morbidity profile and OS in
resected patients, and to determine intent-to-treat overall and
disease-free survival.
Initial enrolment to the study included patients with locally
advanced pancreas cancer that was unresectable as a result of
vascular involvement of tumour. Tumours were considered to be
unresectable if there was evidence of arterial involvement, includ-
ing encasement of the superior mesenteric artery (SMA) or major
branches of the coeliac axis, or venous encasement not amenable
to resection and reconstruction.As the trial progressed, enrolment
was expanded to include patients with what would currently be
considered ‘borderline resectable tumours’. These included cases
of arterial abutment, but not encasement (<180 ° involvement) or
portal venous involvement that was deemed to be not readily
resectable by multidisciplinary review. The protocol was reviewed
and approved by the Clinical Trials Office Cancer Protocol Review
Committee of the University of Minnesota.
Patient enrolment
Patients aged 18 years with a minimum life expectancy of 12
weeks were eligible for inclusion if they had been diagnosed with
locally advanced, non-metastatic (M0) adenocarcinoma of the
pancreas with staging by computed tomography (CT) and endo-
scopic ultrasound (EUS). Metastatic disease was excluded by CT
of the chest, EUS and CT with i.v. contrast [or magnetic resonance
imaging (MRI)] of the abdomen or pelvis within 30 days prior to
registration. Enrolled patients were required to have started treat-
ment within 60 days of diagnosis. Patients were also required to
have an Eastern Cooperative Oncology Group (ECOG) perform-
ance status of 0–1 documented within 14 days prior to registra-
tion, and to have adequate haematologic, renal and hepatic
parameters, including a white blood cell (WBC) count of
>3000 cells/mm3, absolute neutrophil count (ANC) of >1500/
mm3, a platelet count of 100 000/mm3, haemoglobin of 9.5 g/
dl, serum creatinine within 1.5 times the institutional upper limit
of normal (ULN), total bilirubin of 3 mg/dl, aspartate ami-
notransferase (AST) within four times the institutional ULN,
alanine aminotransferase (ALT) within four times the institu-
tional ULN and alkaline phosphatase within four times the insti-
tutional ULN. Additionally, patients with reproductive potential
were required to use effective contraception during treatment and
for 3 months following chemotherapy. Female patients with
reproductive potential were required to demonstrate a negative
pregnancy test within 7 days of the initiation of treatment and
were forbidden to breastfeed.Any patient with a prior diagnosis of
cancer was required to satisfy all of the following criteria: receipt
of potentially curative treatment; no evidence of prior malignan-
cies for 5 years (excluding non-melanoma skin cancer, and
breast or cervical carcinoma in situ), and no evidence of recur-
rence. Patients must also have been able to give informed consent.
Patients were excluded if they failed tomeet any of the inclusion
criteria and for pancreatic tumour histologies of adenosquamous
carcinoma, ampullary carcinoma, carcinoid, cystadenoma or car-
cinoma, distal common bile duct carcinoma, duodenal carcinoma
and islet cell carcinoma. A history of chronic immunotherapy for
collagen vascular disease or another chronic immunologic abnor-
mality was also an exclusion criterion. Finally, patients were
excluded if they required concomitant use of any of granulocyte
colony-stimulating factor (G-CSF), granulocyte-macrophage CSF
(GM-CSF), oprevelkin, aminoglycoside antibiotics, loop diuretics,
lithium, anticonvulsants, dexamethasone, theophylline, other
myelosuppressive agents, and halogenated antiviral agents.
Study procedures and treatments
All patients underwent staging investigations with CT, EUS or
MRI at diagnosis to rule out metastatic disease. All chemotherapy
and radiotherapy were delivered at the University of Minnesota
Medical Center. Figure 1 describes the treatment strategy. All
patients were scheduled to receive one cycle of combination CRT
followed by two cycles of chemotherapy alone. Resectability was
comprehensively re-evaluated after each cycle. For the purposes of
this study, patients required a central venous catheter (CVC) (e.g.
PortaCath, Hickman, PICC), which was removed following the
completion of therapy. Doses were modified before each subse-
quent cycle of treatment based on a recalculation of body surface
area.
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Combination chemotherapy
All patients began chemotherapy within 60 days of enrolment.
The regimen of cycle 1 included 5-FU administered by continu-
ous infusion through a CVC using an ambulatory infusion pump
at 175 mg/m2/day for 38 consecutive days (days 1–38), unless
limited by toxicity. Cisplatin was infused on the first day only of
each week for 6 weeks (i.e. days 1, 8, 15, 22, 29, 36). IFN-a-2b was
given at 3 million units subcutaneously on days 1, 3 and 5 of each
week until day 38. Figure 1 summarizes the treatment schedule.
Radiotherapy
Total radiation of 50.4 Gy was given concurrently with cycle 1
of combination chemotherapy. Radiation therapy was given in
28 fractions, at 180 cGy/fraction daily, on Monday–Friday, for
38 days.
Restaging
Patients were restaged by CT scanning at 2 weeks after the com-
pletion of cycle 1 and 2 weeks after each subsequent cycle as
required. In the absence of metastatic disease, special attention
was paid to the locally advanced tumour, taking into considera-
tion growth and regression as they relate to resectability. If resecta-
bility was still undefined, a repeat EUS was performed by the
original practitioner (if possible) and any pertinent tissues were
sampled as required. If resection was deemed possible after multi-
disciplinary review, surgery was recommended. This protocol was
repeated after each cycle to determine resectability in patients who
did not respond to therapy, but had no demonstrable metastatic
disease.
Surgery
Surgical exploration started with a diagnostic laparoscopy. If no
evidence of carcinomatosis, liver metastases or other metastatic
disease was encountered, a laparotomy was performed. In the
absence of clear technical unresectability, a pancreaticoduodenec-
tomy, distal or total pancreatectomy (and resection of any
involved structures) was performed as mandated by the tumour
anatomy. The operative findings, complications and histopathol-
ogy were recorded.
Cycles 2 and 3 of 5-FU
In patients who underwent surgery, cycle 2 of 5-FU began at 4–10
weeks following recovery from surgery. If patients were found to
be unresectable after cycle 1, post-CRT chemotherapy began in 4
weeks. Patients were given two cycles of chemotherapy with a
2-week rest between cycles. A bolus infusion of 5-FU at 500 mg/
m2/week was administered once per week for 6 weeks (on days 1,
8, 15, 22, 29 and 35 of each cycle) and followed by rest and
restaging (Fig. 1).
Dose modifications
Toxicity and adverse events were classified according to the
National Cancer Institute (NCI) Common Terminology Criteria
for Adverse Events (CTCAE) Version 3.0. The intent was to give a
full course of treatment that followed the treatment plan as closely
as possible and tomake up anymissed doses.During cycle 1, if one
modality (chemotherapy or radiotherapy) was withheld as a result
of toxicity, the other modality was also withheld. Both were
resumed following the resolution of toxicity. If three or more
separate episodes of grade 3 or 4 non-haematologic toxicity
occurred during cycle 1, or three or more separate episodes of
grade 3 or 4 toxicity occurred during cycles 2 and 3, study treat-
ment was terminated in the affected patient.
Statistical analysis
This was a Phase II clinical trial designed to determine if the
therapy could convert patients with locally advanced pancreatic
cancer to candidacy for surgery without excessive toxicity. The
primary endpoint was tumour response (resectability). The
secondary endpoints included toxicity and survival. Simon’s
two-stage design is often used in Phase II clinical trials if only a
primary endpoint is considered. However, the present study
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Figure 1 Treatment protocol in the current Phase II trial of neoadjuvant chemoradiotherapy (CRT) in patients with unresectable pancreatic
cancers. RT, radiotherapy; 5-FU, 5-fluorouracil; CI, continuous infusion
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aimed not only to establish the tumour response rate, but also to
gather additional information about the toxicity associated with
the treatment. Therefore, Bryant and Day’s two-stage design,
which extends Simon’s approach, was used to monitor both
resectability and toxicity. The unacceptable response rate PR0 was
determined to be 0.05 and the acceptable response rate PR1 to be
0.25, with a significance level aR = 0.10 and power 1-bR = 0.90;
thus the study would be considered discouraging if no more than
5% of the study patients were successfully converted to candidacy
for surgical resection (partial response), and would be considered
promising if at least 25% of the cohort were successfully con-
verted. In the VMMC study, only 30.2% (16 of 53) of patients did
not experience toxicity of grade 3 or higher.10 However, in the
present study, the unacceptable rate of non-toxicity (i.e. less than
grade 3 toxicity) PT0 was set at 0.60 and the acceptable rate of
non-toxicity PT1 at 0.80, with a significance level aT = 0.10 and
power 1-bT = 0.90.
The present study group planned to accrue a total of 43
patients. Toxicity and survival were secondary endpoints. Toxicity
data were analysed using a one-sample proportion test. Survival
data include OS in all patients, disease-free survival in resected
patients, locoregional disease control, and distant disease control.
The corresponding survival functions were estimated according to
the Kaplan–Meier method and the predictors for survival were
evaluated by Cox’s proportional hazard model.
Results
A total of 23 patients were enrolled between January 2005 and
October 2010. This trial was halted prematurely as a result of the
incidence of grade 3 and 4 toxicity above the pre-trial predicted
level of 80%. The initial target for enrolment had been 43 patients.
The mean age at enrolment was 58.6 years. Men comprised 73.4%
of the cohort. The majority of the patients were White (69.6%).
Patient demographics are shown in Table 1. Clinical staging
revealed T-stage 3 or 4 disease in 94.1% of patients. Disease stage
based on imaging at trial enrolment is shown in Table 2. Indica-
tions for neoadjuvant treatment included involvement of one or
more of the following: the SMA (180 ° in three patients; >180 °
in one patient); coeliac axis (180 ° in two patients; >180 ° in
three patients); hepatic artery (HA) (>180 ° in six patients),
and/or superior mesenteric vein/portal vein (180 ° in six
patients; >180 ° in seven patients). Of 23 patients, seven (30.4%)
completed all treatments. The remaining 16 (69.6%) patients did
not complete all scheduled treatments as a result of severe side-
effects (n = 7, 30.4%), progressive disease (n = 3, 13%), alternative
treatment (n = 3, 13.0%), patient withdrawal (n = 1, 4.3%), other
disease (n = 1, 4.3%), and death during the study (n = 1, 4.3%).
These findings are summarized in Table 3. Overall, grade 3 or 4
toxicity occurred in 19 (82.6%) patients. Hospitalization for tox-
icity was required in 11 (47.8%) patients. The most commonly
reported grade 3 or 4 toxicities were leucopoenia/cytopoenia (n =
19, 82.6%) and gastrointestinal toxicity (n = 19, 82.6%). Numbers
of patients experiencing grade 3 and 4 toxicity are summarized in
Table 4. Other toxicities were much less common (fatigue, weight
loss, pain, skin rash; all n < 3). Complete details regarding specific
toxicities, their severity and the point in the trial at which the
toxicity occurred are summarized in Table 5. The single death that
occurred during this study was caused by ascending cholangitis in
an individual in whom a plastic biliary stent had been placed prior
to neoadjuvant treatment. The stent became occluded and the
patient developed ascending cholangitis. Despite immediate cor-
rection of the obstruction and aggressive antibiosis, the patient
died. Subsequently, all patients receiving neoadjuvant therapy
for pancreatic head cancers at this institution have been decom-
pressed with metal stents because these stents have superior
patency.
Table 1 Demographic information
Age, years, mean  SD 58.6  9.01
Gender, n (%)
Male 17 (73.9%)
Female 6 (26.1%)
Ethnicity, n (%)
American Indian/Alaska Native 1 (4.3%)
African-American 4 (17.4%)
White 16 (69.6%)
Unknown 2 (8.7%)
SD, standard deviation.
Table 2 Disease information at study onset
T-stage Patients, n (%) (n = 17)
2 1 (5.9%)
3 11 (64.7%)
4 5 (29.4%)
N-stage (n = 16)
0 13 (81.3%)
1 3 (18.7%)
Table 3 Summary of reasons for off-treatment and off-study shifts
Reasons for stopping treatment Patients, n (%)
Treatment completed 7 (30.4%)
Progressive disease or relapse 3 (13.0%)
AE, side-effects, complications 7 (30.4%)
Death on study 1 (4.3%)
Patient withdrawal 1 (4.3%)
Alternative treatment 3 (13.0%)
Other disease 1 (4.3%)
Reasons for withdrawing from study (n = 16)
Patient withdrawn 15 (93.7%)
Death 1 (6.3%)
AE, adverse events.
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Following chemoradiation, all patients underwent restaging
studies to evaluate for evidence of tumour regression and the
possibility of surgical resection. Carbohydrate antigen 19-9 (CA
19-9) values were also obtained pre- and post-treatment. Median
CA 19-9 values were 286 U/ml (range: 1–10 046 U/ml) pre-
treatment and 155 U/ml (range: 19–2500 U/ml) post-treatment.
This difference did not achieve statistical significance.No evidence
of tumour regression was identified in any patient based on CT or
EUS imaging. Conversely, progressive disease precluding surgical
intervention was noted in three individuals.
Surgical resection was ultimately successful in seven (30.4%)
patients. Two patients underwent distal pancreatectomy and
splenectomy and five underwent pancreaticoduodenectomy.
Venous resection and reconstruction were required during one
pancreaticoduodenectomy, although post-treatment imaging sug-
gested venous involvement in all five patients. No patient in whom
arterial encasement had been observed pre-treatment was ulti-
mately downstaged and resected. All of the patients brought to the
operating room for exploration were ultimately resected. No
operative palliative bypass procedures were performed. All surgi-
cal margins were negative in six of seven (85.7%) patients. One
patient, who underwent a Whipple procedure, had microscopi-
cally positive margins at the retroperitoneal/uncinate margin and
the proximal bile duct margin. No grossly positive (R2) margins
were identified in this series. Positive lymph nodes were identified
in three of seven (42.9%) patients. The mean lymph node count
was 11.
Pathologic evaluation of all resected specimens revealed evi-
dence of significant systemic treatment effect in three of seven
(42.9%) patients. In these patients, extensive therapy-induced
regressive changes were identified and only a few microscopic foci
of tumour remained. Figure 2 shows a photomicrograph of a
near-complete response, in which a single malignant gland
remained within the muscularis of the duodenal wall. No com-
plete pathologic responses were identified in this trial.
Mean OS in all patients enrolled in this trial was 11.5 months.
Surgical resection provided significantly improved survival (22.6
months) compared with CRT alone (8.8 months). Disease-free
survival in resected patients was 17.2 months (Fig. 3). Overall
survival in individuals with pathologic evidence of tumour
response to therapy did not differ significantly from that in
patients who showed no evidence of response.
Discussion
This trial represents a novel effort to use IFN-based chemoradia-
tion in the neoadjuvant setting in patients with locally advanced
pancreatic cancer. Ultimately, seven of 23 tumours (30.4%) were
brought to resection, all but one of which were removed with
negative surgical margins.Although this is encouraging, it must be
weighed against the high toxicity of this regimen, which resulted
in one death during this trial.
The primary endpoint of the present study referred to ability to
convert initially non-resectable tumours to resectable status, in
Table 4 Incidences of grade 3 or grade 4 toxicity in the 23 enrolled patients
CRT and 4-week
rest, n (%)
5-FU, n (%) End of trial, n (%)
Blood/bone marrow 19 (82.6%) 4 (17.4%) 2 (8.7%)
Leukocytes/total WBC 11 (47.8%) 3 (13.0%) 1 (4.3%)
Neutrophils/granulocytes (ANC/AGC) 6 (26.1%) 1 (4.3%) 1 (4.3%)
Platelets 2 (8.7%) 1 (4.3%)
Gastrointestinal 19 (82.6%) 2 (8.7%) 0%
Anorexia 7 (30.4%)
Dehydration 2 (8.7%)
Diarrhoea 1 (4.3%)
Mucositis/stomatitis – oral cavity 3 (13.0%)
Nausea 4 (17.4%) 2 (8.7%)
Vomiting 2 (8.7%)
Constitutional symptoms 4 (17.4%) 0% 0%
Fatigue (asthenia, lethargy, malaise) 3 (13.0%)
Weight loss 1 (4.3%)
Dermatology/skin 1 (4.3%) 0% 0%
Rash/hand foot skin reaction 1 (4.3%)
Pain 1 (4.3%) 0% 0%
Pain – abdomen NOS 1 (4.3%)
CRT, chemoradiotherapy; 5-FU, 5-fluorouracil; WBC, white blood cell; ANC/AGC, absolute neutrophil/granulocyte count; NOS, not otherwise
specified.
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Table 5 Maximum severity of toxicity per patient (n = 23)
Pre-study CRT and 4-week rest 5-FU End of treatment
Blood/bone marrow
Grade 1 7 (30.4%) 2 (8.7%) 7 (58.3%)
Grade 2 9 (39.1%) 2 (16.7%)
Grade 3 10 (43.5%) 3 (25.0%) 1 (4.3%)
Grade 4 1 (4.3%)
Cardiac general
Grade 1 1 (4.3%)
Constitutional symptoms
Grade 1 3 (13.0%) 5 (21.7%) 4 (33.3%) 1 (4.3%)
Grade 2 13 (10.2%) 3 (25.0%)
Grade 3 3 (13.0%)
Grade 4
Dermatology/skin
Grade 1 6 (26.1%) 2 (16.7%)
Grade 2 5 (21.7%) 2 (16.7%)
Grade 3 1 (4.3%)
Grade 4
Endocrine
Grade 1 1 (4.3%)
Gastrointestinal
Grade 1 8 (34.8%) 2 (8.7%) 5 (41.7%)
Grade 2 10 (43.5%) 3 (25.0%) 1 (4.3%)
Grade 3 10 (43.5%) 2 (16.7%)
Grade 4 1 (4.3%)
Infection
Grade 1 1 (4.3%) 1 (4.3%)
Grade 2 1 (8.3%)
Grade 3
Grade 4
Lymphatics
Grade 1 1 (8.3%)
Metabolic/laboratory
Grade 1 5 (21.7%) 13 (56.5%) 5 (41.7%)
Grade 2 6 (26.1%) 4 (33.3%) 1 (4.3%)
Grade 3
Grade 4
Neurology
Grade 1 2 (8.7%) 1 (8.3%)
Grade 2 3 (13.0%)
Grade 3
Grade 4
Ocular/visual
Grade 1 1 (4.3%) 1 (8.3%)
Pain
Grade 1 10 (43.5%) 9 (39.1%) 6 (50.0%)
Grade 2 1 (4.3%) 1 (8.3%)
Grade 3 1 (13.0%)
Grade 4
Pulmonary/upper respiratory
Grade 1 1 (4.3%) 3 (13.0%)
Grade 2 1 (4.3%)
Grade 3
Grade 4
Renal/genitourinary
Grade 1 1 (8.3%)
CRT, chemoradiotherapy; 5-FU, 5-fluorouracil.
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which the study demonstrated promising results indicated by the
removal of 30.4% of these tumours. When the protocol for this
trial was written, the current definitions of ‘locally advanced’ and
‘borderline resectable’ cancer were not well established. Initially,
only individuals with locally advanced unresectable disease were
enrolled in this trial, the ultimate goal of which was to convert
some of these individuals to resectable status. As the trial pro-
gressed, enrolment of patients who would now be considered as
borderline resectable was allowed. All patients were reviewed by a
multidisciplinary team and enrolled patients were considered to
have disease that was not readily resectable as a result of vascular
involvement. The present results indicate that all patients who
were ultimately resected had what would now be considered bor-
derline disease at presentation based on the extent of vascular
involvement of the tumours. No patient in whom the SMA,
coeliac axis or HA was encased by tumour was ultimately able to
be resected. In addition, imaging evidence of tumour response to
therapy was essentially non-existent, with no patient demonstrat-
Figure 2 Microphotograph of infiltrative malignant glands within the muscularis propria. The duodenal lumen is on the left; benign pancreatic
parenchyma with features of chronic pancreatitis is on the right. (Magnification ¥1)
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ing a significant reduction in tumour volume during chemoradia-
tion based on staging CT and EUS. Although these findings are
disappointing, those on pathologic examination of the resected
specimens were significantly more encouraging. Of the seven
specimens removed, three (42.9%) showed significant pre-
treatment effects with extensive therapy-induced regressive
changes and only small islands of viable tumour cells remaining.
In addition, in six of seven patients, tumours were resected with
negative margins and only three of these seven patients were
found to have lymph node involvement.Despite initial evidence of
vascular invasion, only one individual in this group required
portal vein resection in order to achieve negative margins. These
factors indicate clearly that pre-treatment chemoradiation does
provide a therapeutic effect.
Despite these seemingly positive findings, OS in individuals
with evidence of tumour response did not improve compared
with that in patients with no pathologic evidence of treatment
response.
The fact that all patients demonstrated apparently significant
vascular involvement but only one of five pancreaticoduodenec-
tomies required venous resection raises concern that post-
treatment imagingmay not accurately reflect tumour resectability.
Similar concerns are raised by the fact that the majority of these
tumours were resected with negative margins, despite locally
advanced disease. This trial did not explore patients for resecta-
bility if they had evidence of arterial encasement on post-
treatment imaging. It is possible that additional patients may have
been resectable, given current knowledge of the accuracy of CT
scans following chemoradiation. Based on the results of this study,
in the absence of tumour progression, the present group currently
explores all patients for resectability following neoadjuvant
therapy at this institution.
With reference to toxicity, the present findings support the
observations of previous investigators.Over 80% of patients in the
present trial suffered grade 3 or 4 toxicity as a result of treatment,
which caused the trial to be halted prematurely. Although most
instances of toxicity were non-life threatening, almost 50% of
patients required hospitalization and one patient died as a result
of treatment. It had been hoped initially that giving treatment
prior to major surgical resection might enable patients to tolerate
it better and to experience fewer severe side-effects. As the present
findings show, this was not the case. Like the present observations,
the results of ACOSOG Z0503112 also confirmed a significant
toxicity associated with this regimen. In that study, 95% of
patients experienced grade 3 or 4 toxicity (66% grade 3, 29%
grade 4).12 In addition, only 17% of patients were able to complete
all chemoradiation,12 whereas 30.4% did so in the present study.
The issue of severe systemic toxicity continues to plague efforts to
assess the full potential of IFN-based combination therapy.
The utility of neoadjuvant therapy in pancreatic cancer has now
been widely published. Even in the absence of a survival advantage
for individuals receiving neoadjuvant therapy, several other
potential advantages must be considered. Firstly, neoadjuvant
therapy allows immediate treatment for what is almost always
systemic disease at the time of diagnosis. It ensures all patients will
receive some form of systemic treatment, whereas in the adjuvant
setting, a significant number of patients may not receive therapy
following surgery. Secondly, neoadjuvant therapy allows the treat-
ment of a tumour in situ, with an uncompromised blood supply
and intact anatomy. Thirdly, neoadjuvant therapy allows for better
patient selection as some individuals will have rapid tumour pro-
gression during systemic treatment. These cases are almost certain
to gain no benefit from surgical resection.
In a recent meta-analysis of neoadjuvant therapy for pancreas
adenocarcinoma, Assifi et al. found that of 134 patients, 31.6% of
those with borderline and locally advanced tumours ultimately
underwent resection following neoadjuvant treatment.13 Median
survival was 22 months in individuals who underwent resection,
whereas OS in all patients was 11 months. These findings are
virtually identical to the observations in the present study. Also in
Assifi et al.’s analysis, 46% of patients with locally advanced
disease had grade 3 or 4 toxicity, according to the results reported
from nine studies.13 This is significantly less than the proportion
observed in any trial including an IFN-based chemoradiation
regimen.13
The present study lends support to the principle of using neo-
adjuvant therapy in patients with locally advanced pancreatic
adenocarcinomas with the ultimate aim of facilitating surgical
resection. The benefit seen in the present trial was limited to those
cancers that are truly borderline, based on < 180 ° abutment of
major arterial structures. In patients with locally advanced disease
made unresectable by arterial encasement, surgical resection was
not possible. Encased vessels did not subsequently become non-
encased and therefore these tumours remained unresectable.
Given this, the present data support the proposals of others that
aggressive neoadjuvant protocols should continue to be focused
on those with borderline resectable disease, in whom the likeli-
hood of achieving surgical therapy is most reasonable.
Since the initiation of this trial, several other neoadjuvant regi-
mens have been investigated in Phase II trials with fairly similar
outcomes in terms of OS. The present group felt that this IFN-
based chemoradiation regimen held promise as the most effective
therapy to date for pancreatic adenocarcinoma. Although the
initial trial from the VMMC10 held significant promise, confirma-
tory trials have failed to reproduce its exceptional outcomes.
Meanwhile, treatment-related toxicity has become a major
problem and has caused many oncologists to hesitate to use such
a regimen. Given the toxicity of this protocol, and its failure to
show significantly improved outcomes over other less toxic regi-
mens, efforts must continue to focus on identifying new drug
combinations that provide tumour response while minimizing
systemic toxicity.
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